Bugula neritina

Bugula neritina
	The nudibranch Diaphorodoris papillata Portmann & Sandmeier, 1960 feeding on Bugula neritina (Linnaeus, 1758)
Scientific classification
Kingdom:	Animalia
Phylum:	Bryozoa
Class:	Gymnolaemata
Order:	Cheilostomata
Family:	Bugulidae
Genus:	Bugula
Species:	B. neritina
Binomial name
	Bugula neritina; (Linnaeus, 1758)[1]
Synonyms[2]
	Sertularia neritina Linnaeus, 1758 (basionym)

Bugula neritina (commonly known as brown bryozoan or common bugula) is a cryptic species complex of sessile marine animal in the genus Bugula.[2]

It is invasive with a cosmopolitan distribution.[1]

Bugula neritina is of interest from a drug discovery perspective because its bacterial symbiont, Candidatus Endobugula sertula[3], produces the bryostatins, a group of around twenty bioactive natural products. The bryostatins are under investigation for their therapeutic potential directed at cancer immunotherapy[4][5], treatment of Alzheimer's disease[5][6], and HIV/AIDS eradication[7], due to their low toxicity and antineoplastic activity.[8]

Bugula neritina is also of interest in materials science, where it is used as a model organism in biofouling studies.[9]

References

"Bugula neritina (brown bryozoan)". CABI (organisation). 3 May 2013. Retrieved 14 March 2015.
Gordon, D. (2015). Bugula neritina (Linnaeus, 1758). In: Bock, P.; Gordon, D. (2015) World List of Bryozoa. Accessed through: World Register of Marine Species at http://www.marinespecies.org/aphia.php?p=taxdetails&id=111158 on 2015-09-02
Li, Hai; Mishra, Mrinal; Ding, Shaoxiong; Miyamoto, Michael M. (2018-08-23). "Diversity and Dynamics of "Candidatus Endobugula" and Other Symbiotic Bacteria in Chinese Populations of the Bryozoan, Bugula neritina". Microbial Ecology. 77 (1): 243–256. doi:10.1007/s00248-018-1233-x. ISSN 0095-3628. PMID 30141128.
Singh R, Sharma M, Joshi P, Rawat DS (2008). "Clinical status of anti-cancer agents derived from marine sources". Anticancer Agents Med Chem. 8 (6): 603–617. doi:10.2174/187152008785133074. PMID 18690825.
Ruan BF, Zhu HL (2012). "The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development". Curr Med Chem. 19 (16): 2652–64. doi:10.2174/092986712800493020. PMID 22506770.
"Bryostatin – Phase II clinical testing of a non-toxic PKC activator". Blanchette Rockefeller Neurosciences Institute (West Virginia University). Retrieved 14 March 2015.
Wender, P. A.; Kee, J.-M.; Warrington, J. M. (2008-05-02). "Practical Synthesis of Prostratin, DPP, and Their Analogs, Adjuvant Leads Against Latent HIV". Science. 320 (5876): 649–652. Bibcode:2008Sci...320..649W. doi:10.1126/science.1154690. ISSN 0036-8075. PMC 2704988. PMID 18451298.
Figuerola, Blanca; Avila, Conxita (2019-06-04). "The Understudied Phylum Bryozoa as a Promising Source of Anticancer Drugs". doi:10.20944/preprints201906.0029.v1. Cite journal requires |journal= (help)
Yua X, Yana Y, Gua JD (2007). "Attachment of the biofouling bryozoan Bugula neritina larvae affected by inorganic and organic chemical cues". Int Biodeterior Biodegradation. 60 (2): 81–89. doi:10.1016/j.ibiod.2006.12.003.

Linnaeus, C. (1758). Systema Naturae per regna tria naturae, secundum classes, ordines, genera, species, cum characteribus, differentiis, synonymis, locis. Editio decima, reformata. Laurentius Salvius: Holmiae. ii, 824 pp

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[CABI2013-1] "Bugula neritina (brown bryozoan)". CABI (organisation). 3 May 2013. Retrieved 14 March 2015.

[WoRMS-2] Gordon, D. (2015). Bugula neritina (Linnaeus, 1758). In: Bock, P.; Gordon, D. (2015) World List of Bryozoa. Accessed through: World Register of Marine Species at http://www.marinespecies.org/aphia.php?p=taxdetails&id=111158 on 2015-09-02

[3] Li, Hai; Mishra, Mrinal; Ding, Shaoxiong; Miyamoto, Michael M. (2018-08-23). "Diversity and Dynamics of "Candidatus Endobugula" and Other Symbiotic Bacteria in Chinese Populations of the Bryozoan, Bugula neritina". Microbial Ecology. 77 (1): 243–256. doi:10.1007/s00248-018-1233-x. ISSN 0095-3628. PMID 30141128.

[RMP2008-4] Singh R, Sharma M, Joshi P, Rawat DS (2008). "Clinical status of anti-cancer agents derived from marine sources". Anticancer Agents Med Chem. 8 (6): 603–617. doi:10.2174/187152008785133074. PMID 18690825.

[BH2012-5] Ruan BF, Zhu HL (2012). "The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development". Curr Med Chem. 19 (16): 2652–64. doi:10.2174/092986712800493020. PMID 22506770.

[6] "Bryostatin – Phase II clinical testing of a non-toxic PKC activator". Blanchette Rockefeller Neurosciences Institute (West Virginia University). Retrieved 14 March 2015.

[7] Wender, P. A.; Kee, J.-M.; Warrington, J. M. (2008-05-02). "Practical Synthesis of Prostratin, DPP, and Their Analogs, Adjuvant Leads Against Latent HIV". Science. 320 (5876): 649–652. Bibcode:2008Sci...320..649W. doi:10.1126/science.1154690. ISSN 0036-8075. PMC 2704988. PMID 18451298.

[8] Figuerola, Blanca; Avila, Conxita (2019-06-04). "The Understudied Phylum Bryozoa as a Promising Source of Anticancer Drugs". doi:10.20944/preprints201906.0029.v1. Cite journal requires |journal= (help)

[XYJ-D2007-9] Yua X, Yana Y, Gua JD (2007). "Attachment of the biofouling bryozoan Bugula neritina larvae affected by inorganic and organic chemical cues". Int Biodeterior Biodegradation. 60 (2): 81–89. doi:10.1016/j.ibiod.2006.12.003.